LLY

1,008.91

-3.56%↓

JNJ

245.26

-2.05%↓

ABBV

233.8

+0.06%↑

NVS

162.28

-2.9%↓

MRK

119.83

-2.59%↓

LLY

1,008.91

-3.56%↓

JNJ

245.26

-2.05%↓

ABBV

233.8

+0.06%↑

NVS

162.28

-2.9%↓

MRK

119.83

-2.59%↓

LLY

1,008.91

-3.56%↓

JNJ

245.26

-2.05%↓

ABBV

233.8

+0.06%↑

NVS

162.28

-2.9%↓

MRK

119.83

-2.59%↓

LLY

1,008.91

-3.56%↓

JNJ

245.26

-2.05%↓

ABBV

233.8

+0.06%↑

NVS

162.28

-2.9%↓

MRK

119.83

-2.59%↓

LLY

1,008.91

-3.56%↓

JNJ

245.26

-2.05%↓

ABBV

233.8

+0.06%↑

NVS

162.28

-2.9%↓

MRK

119.83

-2.59%↓

Search

Quidel Corp

Open

21.18 -2.84

Overview

Share price change

24h

Current

Min

21.53

Max

22.67

Key metrics

By Trading Economics

Employees

6,500

Recommendations

By TipRanks

Recommendations

Neutral

12 Months Forecast

+35.22% upside

Dividends

By Dow Jones

Next Earnings

6 maj 2026

Market Stats

By TradingEconomics

Market Cap

-448M

1.2B

Previous open

24.02

Previous close

21.18

Quidel Corp Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

2 mar 2026, 23:41 UTC

Market Talk
Major News Events

Nikkei May Decline on Concerns About Energy Prices -- Market Talk

2 mar 2026, 23:37 UTC

Market Talk
Major News Events

Gold Edges Higher Amid Middle East Conflict -- Market Talk

2 mar 2026, 23:26 UTC

Major News Events

How the Iran Conflict Could Pressure Consumer Staples Companies -- Barrons.com

2 mar 2026, 22:41 UTC

Market Talk

Australian Reits Wait on Recovery in Trading Multiples -- Market Talk

2 mar 2026, 22:32 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

2 mar 2026, 22:32 UTC

Market Talk

RBA Cautious About Potential for Energy Supply Shocks -- Market Talk

2 mar 2026, 22:21 UTC

Market Talk

Port of Tauranga's Upgraded Profit View Still Looks Conservative -- Market Talk

2 mar 2026, 22:11 UTC

Market Talk

Global Equities Roundup: Market Talk

2 mar 2026, 22:11 UTC

Market Talk

Don't Lose Sight of Bigger Picture With Summerset -- Market Talk

2 mar 2026, 22:10 UTC

Acquisitions, Mergers, Takeovers

IAC Is Near Deal to Sell Care.com to Private-Equity Firm -- WSJ

2 mar 2026, 22:06 UTC

Market Talk

Channel Infrastructure's Dividend Positively Surprises -- Market Talk

2 mar 2026, 22:00 UTC

Market Talk
Earnings

Global Forex and Fixed Income Roundup: Market Talk

2 mar 2026, 22:00 UTC

Market Talk
Earnings

Fashion Retailer Hallenstein Glasson Still a Smart Buy -- Market Talk

2 mar 2026, 21:50 UTC

Market Talk
Major News Events

Energy & Utilities Roundup: Market Talk

2 mar 2026, 21:50 UTC

Market Talk
Major News Events

Basic Materials Roundup: Market Talk

2 mar 2026, 21:50 UTC

Market Talk

Health Care Roundup: Market Talk

2 mar 2026, 21:35 UTC

Acquisitions, Mergers, Takeovers

AT&T Expects Net Debt-To-Adjusted Ebitda Ratio Will Rise to About 3.2x Following Deal With EchoStar and Decline to About 3x by End of 2026

2 mar 2026, 21:34 UTC

Acquisitions, Mergers, Takeovers

AT&T Remains on Track to Achieve Its 2026 and Multi-Yr Fincl Guidance

2 mar 2026, 21:30 UTC

Acquisitions, Mergers, Takeovers

Update: AES to Be Taken Private in $33 Billion Deal. Why It's the S&P 500's Worst Stock Today. -- Barrons.com

2 mar 2026, 21:17 UTC

Major News Events

Bank, Brokerage Stocks Recover Lost Ground After Last Week's Selloff -- Despite Iran Conflict -- Barrons.com

2 mar 2026, 20:44 UTC

Earnings

Berkshire Stock Falls 5% as Earnings, Abel Letter Fail to Excite Investors -- Barrons.com

2 mar 2026, 20:43 UTC

Market Talk
Major News Events

Treasury Yields Fall, Dollar Strengthens After Attack on Iran -- Market Talk

2 mar 2026, 20:28 UTC

Earnings

Strategy Stock Rises. The World's Largest Bitcoin Holder Doubles Down on Its Crypto Bet. -- Barrons.com

2 mar 2026, 20:25 UTC

Market Talk
Major News Events

U.S. Natural Gas Futures Post Moderate Gains -- Market Talk

2 mar 2026, 20:24 UTC

Earnings

Berkshire Stock Falls 5% as Earnings, Abel Letter Fail to Excite Investors -- Barrons.com

2 mar 2026, 20:14 UTC

Acquisitions, Mergers, Takeovers

Update: AES to Be Taken Private in $33 Billion Deal. Why It's the S&P 500's Worst Stock Today. -- Barrons.com

2 mar 2026, 20:12 UTC

Major News Events

Palantir Rises on Mideast Conflict. Why It's Moving Like a Defense Stock. -- Barrons.com

2 mar 2026, 20:08 UTC

Market Talk
Major News Events

Global Forex and Fixed Income Roundup: Market Talk

2 mar 2026, 20:08 UTC

Market Talk
Major News Events

Higher Oil Prices Could Boost Capex in Canada Energy Patch -- Market Talk

2 mar 2026, 20:05 UTC

Market Talk
Major News Events

Oil Rises On U.S.-Middle East Conflict, But Settles Off Highs -- Market Talk

Peer Comparison

Price change

Quidel Corp Forecast

Price Target

By TipRanks

35.22% upside

12 Months Forecast

Average 30.75 USD  35.22%

High 38 USD

Low 25 USD

Based on 5 Wall Street analysts offering 12 month price targets forQuidel Corp - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

5 ratings

1

Buy

3

Hold

1

Sell

Financials

$

About Quidel Corp

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides instruments and tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was incorporated in 1979 and is headquartered in San Diego, California.
help-icon Live chat